Tags: FDA


FDA release on Intrarosa approval omits important conflict of interest


FDA release offers inadequate presentation of auto-inflammatory drug approval


FDA release on hepatitis C drug informs on harms, benefits but is light on evidence

1 5/24/2016

FDA PR release on bladder cancer drug skirts lack of long-term survival data

1 5/10/2016

FDA release on drug for treating Parkinson’s psychosis lacks some key details


FDA skims over benefits and costs of cooling cap it approved for reducing hair loss during chemo